242 results on '"Holderried, Tobias A."'
Search Results
2. Cardiovascular Magnetic Resonance Assessment of Immunotherapy Cardiotoxicity
3. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)
4. Whole body irradiation with intensity-modulated helical tomotherapy prior to haematopoietic stem cell transplantation: analysis of organs at risk by dose and its effect on blood kinetics
5. Total marrow irradiation versus total body irradiation using intensity-modulated helical tomotherapy
6. Hospital sanitary facilities on wards with high antibiotic exposure play an important role in maintaining a reservoir of resistant pathogens, even over many years
7. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
8. Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany
9. Antibiotic Prophylaxis During Allogeneic Stem Cell transplantation—A Comprehensive Single Center Retrospective Analysis
10. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
11. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
12. Systematic Review and Meta-Analysis of Extracorporeal Photopheresis for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease
13. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)
14. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
15. Optimized Conformal Total Body Irradiation with VMAT Using a Linear-Accelerator-Based Radiosurgery Treatment System in Comparison to the Golden Standard Helical TomoTherapy
16. P1387: TREATMENT WITH A LEUKEMIA-DERIVED DENDRITIC CELL VACCINE INDUCES INNATE AND ADAPTIVE IMMUNE RESPONSE CORRELATING WITH CLINICAL RESPONSE IN AML PATIENTS IN CR1 WITH MEASURABLE RESIDUAL DISEASE
17. The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin’s Lymphoma
18. Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome
19. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma
20. Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma
21. Evaluation of factors associated with survival in allogeneic stem cell-transplanted patients admitted to the intensive care unit (ICU).
22. The potential of eHealth for cancer patients–does COVID-19 pandemic change the attitude towards use of telemedicine services?
23. Peripheral blood kinetics following total body irradiation and allogeneic hematopoietic stem cell transplantation: Timing matters
24. Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens
25. Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion
26. The Potential of E-Health in Patients after Allogeneic Stem Cell Transplantation
27. 713 The PRAME opportunity – high peptide copy numbers, homogenous expression and high prevalence to address a broad patient population across different solid cancers with TCR-based therapeutics
28. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
29. Stable inhibitory activity of regulatory T cells requires the transcription factor Helios
30. Genetic disruption of CD8 + Treg activity enhances the immune response to viral infection
31. On-demand erythrocyte disposal and iron recycling requires transient macrophages in the liver
32. The Potential of E-Health in Patients after Allogeneic Stem Cell Transplantation
33. Peripheral blood kinetics following total body irradiation and allogeneic hematopoietic stem cell transplantation: Timing matters.
34. Eµ-TCL1 Mice Represent a Model for Immunotherapeutic Reversal of Chronic Lymphocytic Leukemia-Induced T-Cell Dysfunction
35. Preliminary Report for the Development of a Multiparameter Protocol for the Identification of Sinusoidal Obstruction Syndrome including Abdominal Ultrasound before and after Allogeneic Stem Cell Transplantation
36. Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
37. Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival
38. Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia
39. 959 Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial
40. ROCKing Chronic Graft-Versus-Host Disease
41. Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients
42. Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine
43. T CELL IMMUNITY: Stable inhibitory activity of regulatory T cells requires the transcription factor Helios
44. Fecal microbiota transfer for refractory intestinal graft‐versus‐host disease — Experience from two German tertiary centers
45. Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility
46. sj-pdf-2-lup-10.1177_0961203321999723 - Supplemental material for Helios-expressing CD8+ T cells are decreased in patients with systemic lupus erythematosus
47. sj-pdf-1-lup-10.1177_0961203321999723 - Supplemental material for Helios-expressing CD8+ T cells are decreased in patients with systemic lupus erythematosus
48. sj-docx-1-tab-10.1177_1759720X211006963 – Supplemental material for Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis
49. sj-docx-2-tab-10.1177_1759720X211006963 – Supplemental material for Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis
50. Fecal microbiota transfer for refractory intestinal graft-versus-host disease - Experience from two German tertiary centers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.